Aura Biosciences, Inc. (AURA)
USD 6.15
(1.32%)
USD 6.15
(1.32%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -63.84 Million | -54.6 Million | -32.41 Million | -24.32 Million | -20.66 Million |
| Net Income | -76.4 Million | -58.76 Million | -35.25 Million | -22.2 Million | -24.2 Million |
| Depreciation & Amortization | 1.29 Million | 1.17 Million | 831 Thousand | 831 Thousand | 509 Thousand |
| Deferred income taxes | 1.04 Million | - | 14 Thousand | - | 11 Thousand |
| Stock-based compensation | 8.77 Million | 6.41 Million | 2.3 Million | 736 Thousand | 507 Thousand |
| Change in working capital | 4.44 Million | -3.1 Million | -315 Thousand | -3.67 Million | 2.46 Million |
| Other non-cash items | -2.98 Million | -325 Thousand | 4000.00 | -3000.00 | 43 Thousand |
| Investing Cash Flow | -113.96 Million | -67.86 Million | -2.12 Million | -771 Thousand | -2.22 Million |
| Investments in PPE | -709 Thousand | -1.09 Million | -2.12 Million | -771 Thousand | -2.22 Million |
| Acquisitions | 113.25 Thousand | 66.77 Thousand | - | - | - |
| Investment purchases | -233.65 Million | -119.78 Million | - | - | - |
| Sales/Maturities of investments | 120.39 Million | 53 Million | - | - | - |
| Other Investing Activities | -113.25 Thousand | -66.77 Thousand | - | - | - |
| Financing Cash Flow | 97.29 Million | 95.62 Million | 166.25 Million | 10.03 Million | 39.72 Million |
| Debt repayment | - | - | - | -34 Thousand | -37 Thousand |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | -13 Thousand |
| Common Stock Issuance | 97.29 Million | 8.54 Million | 78.69 Million | 10.07 Million | 39.76 Million |
| Other Financing Activities | 94.12 Million | 87.08 Million | 87.56 Million | -34 Thousand | 39.77 Million |
| Accounts receivables | - | - | - | - | - |
| Accounts payables | -1.04 Million | 340 Thousand | 1.05 Million | -1.72 Million | 1.04 Million |
| Inventory | - | - | - | - | - |
| Other working capital | 5.48 Million | -3.44 Million | -1.36 Million | -1.95 Million | 1.42 Million |
| Cash at beginning of period | 121.6 Million | 149.21 Million | 17.48 Million | 32.54 Million | 15.7 Million |
| Cash at end of period | 41.08 Million | 122.37 Million | 149.21 Million | 17.48 Million | 32.54 Million |
| Capital Expenditure | -709 Thousand | -1.09 Million | -2.12 Million | -771 Thousand | -2.22 Million |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | -80.52 Million | -26.84 Million | 131.72 Million | -15.05 Million | 16.83 Million |
| Free Cash Flow | -64.55 Million | -55.69 Million | -34.53 Million | -25.09 Million | -22.88 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -20.33 Million | -19.7 Million | -22.13 Million | -76.4 Million | -18.51 Million | -18.29 Million |
| Depreciation & Amortization | 313 Thousand | 306 Thousand | 324 Thousand | 1.29 Million | 343 Thousand | 300 Thousand |
| Deferred income taxes | - | - | -2.79 Million | 1.04 Million | -820 Thousand | -1.02 Million |
| Stock-based compensation | 3.12 Million | 2.9 Million | 2.6 Million | 8.77 Million | 2.32 Million | 1.93 Million |
| Change in working capital | 1.72 Million | -6.8 Million | 2.03 Million | 4.44 Million | 808 Thousand | 1.89 Million |
| Other non-cash items | 3.33 Million | 2.34 Million | 2.57 Million | -2.98 Million | 453 Thousand | 557 Thousand |
| Investing Cash Flow | 19.84 Million | 9.39 Million | -90.12 Million | -113.96 Million | 21.62 Million | 21.4 Million |
| Investments in PPE | -525 Thousand | -88 Thousand | -317 Thousand | -709 Thousand | -90 Thousand | -193 Thousand |
| Acquisitions | - | - | 89.8 Thousand | 113.25 Thousand | - | - |
| Investment purchases | -9.9 Million | -29.2 Million | -144.8 Million | -233.65 Million | - | - |
| Sales/Maturities of investments | 30.27 Million | 38.68 Million | 55 Million | 120.39 Million | 21.71 Million | 21.6 Million |
| Other Investing Activities | 20.36 Million | 9.48 Million | -89.8 Thousand | -113.25 Thousand | 21.71 Thousand | 21.6 Thousand |
| Financing Cash Flow | 83 Thousand | 253 Thousand | 92.98 Million | 97.29 Million | 1.62 Million | 2.47 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 83 Thousand | 253 Thousand | 92.98 Million | 97.29 Million | 1.35 Million | 2.47 Million |
| Other Financing Activities | 83 Thousand | 253 Thousand | 92.98 Thousand | 94.12 Million | 274 Thousand | 2478.00 |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -540 Thousand | 23 Thousand | 457 Thousand | -1.04 Million | 885 Thousand | -501 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 2.26 Million | -6.82 Million | 1.57 Million | 5.48 Million | -77 Thousand | 2.39 Million |
| Cash at beginning of period | 26.27 Million | 41.08 Million | 55.6 Million | 121.6 Million | 48.52 Million | 39.28 Million |
| Cash at end of period | 30.07 Million | 26.27 Million | 41.08 Million | 41.08 Million | 56.37 Million | 48.52 Million |
| Capital Expenditure | -525 Thousand | -88 Thousand | -317 Thousand | -709 Thousand | -90 Thousand | -193 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 3.79 Million | -14.8 Million | -14.52 Million | -80.52 Million | 7.85 Million | 9.24 Million |
| Free Cash Flow | -16.65 Million | -24.54 Million | -17.7 Million | -64.55 Million | -15.49 Million | -14.83 Million |
BLISSGVS
NWG
003490
GSVR
VZN
SFC